м -

ֿ ӻ _2020.12.17
ۼ
Ѱȸ
ۼ
2020-12-17
ȸ
3099


ֿ ӻ



1. Pfizer/BioNTech (BNT162b1 and BNT162b2, mRNA vaccine)

 

   (1) Phase 1/2

- NEJM 2020;383:2439-2450. December 17, 2020, https://doi.org/10.1056/NEJMoa2027906

- Nature 2020 Oct;586(7830):589-593 https://doi.org/10.1038/s41586-020-2639-4

 

   (2) BNT162b2 (Efficienty and safety in an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial)

- NEJM. Online published. December 10, 2020

- https://doi.org/10.1056/NEJMoa203457

 

2. Moderna (mRNA-1273 vaccine)

 

   (1) Preclinical (Nonhuman Primates)

- NEJM 2020;383:1544-1555. October 15, 2020

- https://www.nejm.org/doi/10.1056/NEJMoa2024671

 

   (2) Phase 1

- NEJM 2020;383:1920-1931. November 12, 2020

- https://doi.org/10.1056/NEJMoa2022483



   (3) Older adults phase 1 - 56 to 70 years or ≥71 years, 4 25 μg or 100 μg

- NEJM 2020;383:2427-2438, December 17, 2020

- https://doi.org/10.1056/NEJMoa2028436

 

3. AstraZeneca (Chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19)

 

   (1) Phase 1/2

- Lancet 2020; 396: 467–78. July 20, 2020

- https://doi.org/10.1016/S0140-6736(20)31604-4

 

   (2) Phase 2/3

- Lancet. Published Online November 19, 2020

- https://doi.org/10.1016/S0140-6736(20)32466-1

 

   (3) Interim analysis of ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa

- Lancet. Published Online December 8, 2020

- https://doi.org/10.1016/S0140-6736(20)32661-1

 

4. Sinovac Life Sciences (CoronaVac, rAd5 vectored vaccine )

 

   (1) Phase 1

- Lancet 2020;395:1845–54. May 22, 2020

- https://doi.org/10.1016/S0140-6736(20)31208-3

 

   (2) Phase 2

- Lancet 2020;396:479–88. July 20, 2020

- https://doi.org/10.1016/S0140-6736(20)31605-6

 

   (3) Phase 1/2

- Lancet Infect Dis 2020. Published Online November 17, 2020

- https://doi.org/10.1016/S1473-3099(20)30843-4

 

 

5. Novavax (NVX-CoV2373: rSARS-CoV-2 spike protein nanoparticle vaccine)

 

(1) Phase 1/2

- NEJM 2020;383:2320-2332. December 10, 2020

- https://doi.org/10.1056/NEJMoa2026920

 

 

6. BBIBP-CorV (National Program on Key Research Project of China)

 

(1) Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protectio against SARS-CoV-2

- Cell 2020:182,713–721, August 6, 2020

- https://doi.org/10.1016/j.cell.2020.06.008

 

(2) Phase 1/2

- Lancet Infect Dis 2020 Published Online October 15, 2020

- https://doi.org/10.1016/S1473-3099(20)30831-8

 

7. Ministry of Health of the Russian Federation (rAd26- and rAd5-spike glycoprotein

   vaccine)

 

(1) Phase 1/2

- Lancet 2020;396: 887–97. September 4, 2020

- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext